FDA Approves Gilead’s Lymphoma (Blood cancer) drug idelalisib (Zydelig)

July 23, 2014 9:37 PM

16 0

The Food and Drug Administration (FDA) has given green signal to Gilead Sciences for its drug idelalisib (Zydelig) for treating three types of relapse lymphoma, one of the forms of blood cancer.

While announcing the decision, Richard Pazdur of FDA said that Zydelig (idelalisib) is the third drug which has been approved with an advance designation for treating CLL patients. Moreover, this is the fifth drug overall to receive this breakthrough designation.

Read more

To category page